Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
An estimated 20 to 40 percent of cancer patients receiving certain types of chemotherapy treatments may experience debilitating pain. The pain can cause a number of symptoms including…
NEW YORK (Reuters Health) – Environmental factors appear to influence the incidence of papillary thyroid microcarcinomas (PTMCs), according to a comparison of epidemiologic data from Sicily and the…
NEW YORK (Reuters Health) – In a randomized controlled trial, the anti-CA-125 vaccine abagovomab did not prolong survival in patients with ovarian cancer in first remission — despite…
NEW YORK (Reuters Health) – Even without conventional conditioning and cytoxic chemotherapy, an allogeneic hematopoietic cell transplant (HCT) can have a substantial benefit in patients with advanced hematologic…
NEW YORK (Reuters Health) – Intraperitoneal chemotherapy may significantly improve long-term survival in ovarian cancer patients, a new study found. Data from 876 patients followed for a median…
NEW YORK (Reuters Health) – The risk of arterial thromboembollic events related to bevacizumab treatment of colorectal cancer (CRC) in older patients is moderate in general practice, and…
NEW YORK (Reuters Health) – In cancer patients with a central venous catheter (CVC), the occurrence of a related infection or thrombosis can often be resolved while the…
NEW YORK (Reuters Health) – The rate of incidental thyroid cancer detected among patients who undergo thyroidectomy for apparently benign disease is unexpectedly high, especially in cases of…
NEW YORK (Reuters Health) – Patients with acute myeloid leukemia (AML) who do not receive a stem-cell transplant during first remission and then relapse have a fair chance of…
NEW YORK (Reuters Health) – Anticoagulant use may be a predictor of overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel, retrospective data suggest. The…
